Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.70 |
| ▸ | TYMS | P04818 | 3/20 | 0.70 |
| ▸ | FPGS | Q05932 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | TLR4 | O00206 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.70 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methopterine SCHEMBL2274614 | 0.99 | DHFR (0.69) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL338037 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL29190442 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL25167471 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL28344641 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL16583122 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL869876 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL28135233 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL20486467 | 0.91 | DHFR (0.57) | DHFRTYMSFPGSKDM4EMEN1 | |
| SCHEMBL3771709 | 0.90 | DHFR (0.56) | DHFRTYMSFPGSKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099401-A1 | Hemp Oil/Magnesium Preparation for Cognitive-Enhancement and Reduction of Stress and lnflammation | FP NUTRACEUTICALS, LLC (US) | 2025-03-27 | — | — | US | claimed |
| CN-119679799-A | Folic acid-containing composition, application thereof, orally disintegrating tablet and preparation method | 北京斯利安药业有限公司 | 2025-03-25 | — | — | CN | claimed |
| US-20250090455-A1 | SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS | FP NUTRACEUTICALS, LLC (US) | 2025-03-20 | — | — | US | claimed |
| US-12201623-B1 | Composition and method for preventing long-term COVID-19 morbidity | KLIPPER, MICHAEL | 2025-01-21 | — | — | US | claimed |
| US-20240285704-A1 | COMPOSITIONS COMPRISING ORGANIC MINERAL CHELATES, NIACINAMIDE, AND HEMP OIL AND USES THEREOF FOR NEUROPROTECTION, CARDIOPROTECTION, DETOXIFICATION, IMMUNE SUPPORT, AND ANTI-AGING | HANCOCK WHITNEY BANK | 2024-08-29 | — | — | US | claimed |
| US-20240277750-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | HedoniaUSA, Ave (US) | 2024-08-22 | — | — | US | claimed |
| CN-114344328-B | Composition for reducing gout occurrence risk of hypertensive patient | 深圳奥萨制药有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-117297101-A | Composite nutritional supplement, preparation method and application thereof | 淄博维克勋医药技术有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230372241-A1 | SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS | FP NUTRACEUTICALS, LLC (US) | 2023-11-23 | — | — | US | claimed |
| US-20230372265-A1 | Hemp Oil/Magnesium Preparation for Cognitive-Enhancement and Reduction of Stress and lnflammation | FP NUTRACEUTICALS, LLC (US) | 2023-11-23 | — | — | US | claimed |
| US-20090325949-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-12-31 | — | — | US | claimed |
| EP-1501551-B1 | Folate-receptor targeted imaging agents | ENDOCYTE INC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-2026813-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | Braincells, Inc. (US) | 2009-02-25 | — | — | EP | claimed |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | US | claimed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| EP-0724447-B1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE | ISIS PHARMACEUTICALS INC (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020177150-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICAL, INC. | 2002-11-28 | — | — | US | claimed |
| EP-0724447-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-07 | — | — | EP | claimed |
| EP-0724447-A4 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS INC (US) | 1996-01-22 | — | — | EP | claimed |
| WO-1993007883-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | DHFR 413/4885TYMS 1003/4885FPGS 637/4885 |
| US-20090325949-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | DHFR 413/4885TYMS 1003/4885FPGS 637/4885 |
| US-20240285704-A1 | COMPOSITIONS COMPRISING ORGANIC MINERAL CHELATES, NIACINAMIDE, AND HEMP OIL AND USES THEREOF FOR NEUROPROTECTION, CARDIOPROTECTION, DETOXIFICATION, IMMUNE SUPPORT, AND ANTI-AGING | HAMP, NAMPT, FABP3 | DHFR 1977/4885TYMS 2471/4885FPGS 668/4885 |
| US-20240277750-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | BHMT2, MAT1A, MGMT | DHFR 12/4885TYMS 108/4885FPGS 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.